SG11201503861UA - Immunogenic composition - Google Patents

Immunogenic composition

Info

Publication number
SG11201503861UA
SG11201503861UA SG11201503861UA SG11201503861UA SG11201503861UA SG 11201503861U A SG11201503861U A SG 11201503861UA SG 11201503861U A SG11201503861U A SG 11201503861UA SG 11201503861U A SG11201503861U A SG 11201503861UA SG 11201503861U A SG11201503861U A SG 11201503861UA
Authority
SG
Singapore
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Application number
SG11201503861UA
Inventor
Dominique Boutriau
Sophie Marie Jeanne Valentine Germain
Hugues Wallemacq
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB201221875 priority Critical
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Priority to PCT/EP2013/075405 priority patent/WO2014086787A1/en
Publication of SG11201503861UA publication Critical patent/SG11201503861UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
SG11201503861UA 2012-12-05 2013-12-03 Immunogenic composition SG11201503861UA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201221875 2012-12-05
PCT/EP2013/075405 WO2014086787A1 (en) 2012-12-05 2013-12-03 Immunogenic composition

Publications (1)

Publication Number Publication Date
SG11201503861UA true SG11201503861UA (en) 2015-06-29

Family

ID=49724573

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503861UA SG11201503861UA (en) 2012-12-05 2013-12-03 Immunogenic composition

Country Status (19)

Country Link
US (2) US9694064B2 (en)
EP (2) EP2928489B1 (en)
JP (2) JP6290918B2 (en)
CN (1) CN104884081A (en)
AR (1) AR093712A1 (en)
AU (1) AU2013354186A1 (en)
BR (1) BR112015012841A2 (en)
CA (1) CA2893435A1 (en)
DK (1) DK2928489T3 (en)
ES (1) ES2721930T3 (en)
HR (1) HRP20190711T1 (en)
HU (1) HUE043091T2 (en)
LT (1) LT2928489T (en)
PL (1) PL2928489T3 (en)
SG (1) SG11201503861UA (en)
SI (1) SI2928489T1 (en)
TR (1) TR201905272T4 (en)
WO (1) WO2014086787A1 (en)
ZA (1) ZA201503927B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007016237A (en) * 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Immunogenic composition.
RS55707B1 (en) 2010-09-03 2017-07-31 Valneva Austria Gmbh Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
HUE043091T2 (en) * 2012-12-05 2019-08-28 Glaxosmithkline Biologicals Sa Immunogenic composition
CN107397956A (en) * 2017-08-08 2017-11-28 南开大学 Preparation method and application of pseudomonas aeruginosa outer membrane protein vaccine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health Autocrine motility factors in cancer diagnosis and management.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE69535530D1 (en) 1994-10-24 2007-08-16 Ophidian Pharm Inc Vaccine and anti-toxins for the treatment and prevention of C. difficile disease
JP3755890B2 (en) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) Adjuvanted vaccine composition
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
NZ305365A (en) 1995-04-25 1999-05-28 Smithkline Beecham Biolog A vaccine containing an antigen, an immunologically active saponin and a sterol
WO1999020304A1 (en) 1997-10-20 1999-04-29 Oravax, Inc. Passive immunization against clostridium difficile disease
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP2502998A3 (en) 1999-04-09 2013-02-27 Intercell USA, Inc. Recombinant toxin A/ToxinB vaccine against clostridium difficile
WO2001073030A2 (en) 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
GB0525321D0 (en) * 2005-12-13 2006-01-18 Glaxosmithkline Biolog Sa Novel compositions
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
AU2007306381B2 (en) * 2006-10-12 2011-12-08 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
MX2010002815A (en) 2007-09-14 2010-07-30 Sanofi Pasteur Biologics Co Pharmaceutical compositions containing clostridium difficile toxoids a and b.
HUE026586T2 (en) * 2008-04-16 2016-06-28 Glaxosmithkline Biologicals Sa Vaccine
CA2733425A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
RS55707B1 (en) 2010-09-03 2017-07-31 Valneva Austria Gmbh Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
WO2012163810A1 (en) * 2011-05-27 2012-12-06 Glaxosmithkline Biologicals S.A. Immunogenic composition
HUE043091T2 (en) * 2012-12-05 2019-08-28 Glaxosmithkline Biologicals Sa Immunogenic composition

Also Published As

Publication number Publication date
EP3513806A1 (en) 2019-07-24
PL2928489T3 (en) 2019-07-31
US20170340719A1 (en) 2017-11-30
CA2893435A1 (en) 2014-06-12
HUE043091T2 (en) 2019-08-28
JP2018104446A (en) 2018-07-05
US20150313984A1 (en) 2015-11-05
EP2928489B1 (en) 2019-02-27
JP6290918B2 (en) 2018-03-07
WO2014086787A1 (en) 2014-06-12
BR112015012841A2 (en) 2017-09-26
EP2928489A1 (en) 2015-10-14
JP2016502551A (en) 2016-01-28
AU2013354186A1 (en) 2014-06-12
CN104884081A (en) 2015-09-02
ZA201503927B (en) 2017-11-29
ES2721930T3 (en) 2019-08-06
AR093712A1 (en) 2015-06-17
SI2928489T1 (en) 2019-05-31
DK2928489T3 (en) 2019-04-23
HRP20190711T1 (en) 2019-05-31
TR201905272T4 (en) 2019-05-21
US9694064B2 (en) 2017-07-04
US10130694B2 (en) 2018-11-20
LT2928489T (en) 2019-04-10

Similar Documents

Publication Publication Date Title
GB201215273D0 (en) Nicotine composition
EP2836212A4 (en) Novel compositions and methods
HK1208025A1 (en) Aminoimidazopyridazines
HK1215183A1 (en) Protein-polymer-drug conjugates --
EP2754580A4 (en) Dumptruck
IL235890D0 (en) Vaccine
IL238807D0 (en) Pharmaceutical compositions
ZA201501709B (en) Cosmetic biphotonic compositions
GB201003924D0 (en) Immunogenic composition
GB201220354D0 (en) Dermal compositions
PL2647387T3 (en) Vaccine Composition
EP2934531A4 (en) Combination
GB201015132D0 (en) Vaccine composition
HK1231412A1 (en) Immunogenic composition
SG10201607269YA (en) Sunscreen composition
SG11201503355WA (en) Polishing composition
HUE040914T4 (en) Immunogenic composition
GB201209268D0 (en) Surfactant composition
EP2878636A4 (en) Curable composition
EP2832730A4 (en) Mirabegron-containing pharmaceutical composition
ZA201504119B (en) Cosmetic composition
GB2506426B (en) Composition
EP2911673A4 (en) Combination
HK1200109A1 (en) Ophthalmic composition
EP2930228A4 (en) Cooling-equipment working-fluid composition